Sanofi (SNYNF)
| Previous close | 92.70 |
| Open | 92.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 92.70 - 92.70 |
| 52-week range | 86.12 - 114.90 |
| Volume | |
| Avg. volume | 44,475 |
| Market cap | 115.711B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 20.28 |
| EPS (TTM) | 4.57 |
| Earnings date | N/A |
| Forward dividend & yield | 4.06 (4.38%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
ReutersSanofi to overhaul US operations of vaccines, cut jobs
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
GlobeNewswirePress Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares - March 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
